InMed Pharmaceuticals Inc. (INM) Q3 2021 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning. My name is Sarah, and I will be your conference operator today. At this time, I would like to welcome everyone to NMED's third quarter 2021 financial results and business update conference call for the fiscal quarter ended March 31st, 2021. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star, then the number one on your telephone keypad. If you would like to withdraw your question, Please press the pound key. Thank you. All lines have been placed on mute to prevent any background noise. Mr. Colwell, you may begin your conference. Thank you, sir. Good day, everyone. My name is Bruce Colwell, and I am NMED's Chief Financial Officer. Welcome to NMED's third quarter 2021 financial results and business update conference call. Please note that we are, once again, all joining today from remote locations, so we appreciate your patience if we happen to encounter any unexpected technical challenges today. But before we begin, we would like to go over our disclosure statements, followed by a review of the progress of our therapeutic development and cannabinoid manufacturing programs, which will be led by our President and CEO, Eric Adams, after which I will review the financial results of operations. Following that, we will be available for a question and answer session. We also have joining us today to address your questions, Eric Hsu, Senior Vice President of Preclinical Research and Development, Alexandra Mancini, Senior Vice President, Clinical and Regulatory Affairs, and Michael Woodenberg, Vice President of Chemistry, Manufacturing, and Control. Please be advised that certain statements in the following conference call regarding expectations for InMed's business ope...